StockNews.com Initiates Coverage on Enzo Biochem (NYSE:ENZ)

Analysts at StockNews.com initiated coverage on shares of Enzo Biochem (NYSE:ENZ) in a research note issued on Tuesday. The brokerage set a “hold” rating on the medical research company’s stock.

Enzo Biochem Price Performance

ENZ opened at $1.14 on Tuesday. Enzo Biochem has a 1 year low of $0.99 and a 1 year high of $1.50. The company’s 50 day simple moving average is $1.13 and its 200 day simple moving average is $1.12.

Institutional Trading of Enzo Biochem

An institutional investor recently raised its position in Enzo Biochem stock. XTX Topco Ltd raised its position in shares of Enzo Biochem, Inc. (NYSE:ENZ) by 94.5% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 28,262 shares of the medical research company’s stock after acquiring an additional 13,735 shares during the period. XTX Topco Ltd owned approximately 0.05% of Enzo Biochem worth $31,000 at the end of the most recent reporting period. 36.90% of the stock is currently owned by institutional investors and hedge funds.

About Enzo Biochem

Enzo Biochem, Inc develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis.